AbbVie presented additional data this week on IMBRUVICA (ibrutinib) at the American Society of Clinical Oncology (ASCO) annual meeting.
The longer-term follow up results of the Phase III study in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) show positive results in progression-free survival (PVS) and overall survival (OS) in the studies' participants.
"Our clinical data presented at this year's ASCO from several randomized studies demonstrate solid durability of response with IMBRUVICA in patients with CLL/SLL with additional follow-up of up to three years," Pharmacyclics Head of Oncology Dr. Danelle James said. "This evidence of deepening responses with continued therapy and long-term survival with IMBRUVICA over time, used either as a single agent or in combination, positions this therapy as a potentially beneficial treatment option for a variety of patients with CLL or SLL, regardless of when it is prescribed in the treatment journey."
The long term results from the RESONATE and RESONATE-2 trials found that 89 percent to 92 percent of the patients treated with ibrutinib have remained progression free after two years. The overall response rate (ORR) in previously treated patients was 92 percent and in newly treated patients was 91 percent.
AbbVie also presented the longer term data from the HELIOS trial, which evaluated the combination of IMBRUVICA with bendamustine and rituximab (BR). The follow up data also shows better results in relapsed CLL/SLL patients compared to those treated with a placebo and BR.